Downregulated salt-inducible kinase 3 expression promotes chemoresistance in serous ovarian cancer via the ATP‐binding cassette protein ABCG2

Yu Ling Liang, Chin Han Wu, Chieh Yi Kang, Chang Ni Lin, Neng Yao Shih, Sheng Hsiang Lin, Yeong Chang Chen, Keng Fu Hsu

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Background: Epithelial ovarian cancer (EOC) has a high tumor-associated mortality rate among gynecological cancers. Although CA125 is a well-studied biomarker for ovarian cancer, it is also elevated under numerous conditions, resulting in decreased specificity. Recently, we identified a novel tumor-associated antigen, salt-inducible kinase 3 (SIK3), during tumorigenesis in ovarian cancer. However, the association between SIK3 expression and patient outcomes in ovarian cancer remains unclear. Materials and Methods: We collected EOC samples from 204 patients and examined tumor SIK3 expression by immunohistochemistry (IHC) and CA125 expression in tumors and serum. The expression levels of SIK3 and CA125 were correlated with patient survival. SIK3 expression was silenced with SIK3-specific shRNAs to investigate the possible mechanisms related to chemoresistance in serous-type ovarian cancer cell lines OVCAR4 and SKOV3. Results: In advanced-stage serous ovarian cancer, patients with low SIK3 expression have poorer overall survival (OS) and progression-free survival (PFS) than patients with high SIK3 expression. Ovarian cancer cells with SIK3 knockdown display increased chemoresistance to Taxol plus cisplatin treatment, which is associated with the upregulation of the ABCG2 transporter. In addition, in serous ovarian cancer, SIK3 expression is inversely correlated to ABCG2 expression, and patients with low SIK3 and high ABCG2 expression have worse prognosis than patients with high SIK3 and low ABCG2 expression. Conclusion: Our results demonstrated that serous EOC patients with low SIK3 expression have poor prognosis, which is associated with chemoresistance mediated by ABCG2 upregulation. SIK3 and ABCG2 expression levels may be potential prognostic markers to predict the outcome in serous EOC patients.

Original languageEnglish
Pages (from-to)6025-6036
Number of pages12
JournalJournal of Cancer
Issue number24
Publication statusPublished - 2019

All Science Journal Classification (ASJC) codes

  • Oncology


Dive into the research topics of 'Downregulated salt-inducible kinase 3 expression promotes chemoresistance in serous ovarian cancer via the ATP‐binding cassette protein ABCG2'. Together they form a unique fingerprint.

Cite this